SCHEMBL30765993

SCHEMBL30765993

O=C(O)Cn1c(-c2ccccc2)ncc(N2C=Cc3ccccc3C2)c1=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ELANE P08246 3/20 0.35
HPGD P15428 3/20 0.34
ALDH1A1 P00352 2/20 0.34
AKR1B10 O60218 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CMA1 P23946 1/20 0.33
CTRC Q99895 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HDAC3 O15379 1/20 0.32
ALOX15 P16050 1/20 0.32
APEX1 P27695 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765587 0.81 KDM4E (0.42) KDM4EHSD17B10MEN1KMT2AELANE
SCHEMBL30765650 0.78 NTRK1 (0.40) ALDH1A1CMA1CTRC
SCHEMBL30765677 0.71 KDM4E (0.49) KDM4EHSD17B10ELANEHPGDALDH1A1
SCHEMBL6239360 0.70 CMA1 (0.53) KDM4EHSD17B10ELANECMA1CTRC
SCHEMBL30765727 0.70 KDM4E (0.44) KDM4EHSD17B10MEN1KMT2AELANE
SCHEMBL6804111 0.69 CMA1 (0.53) KDM4EHSD17B10ELANECMA1CTRC
Hydrochloric Acid SCHEMBL6805327 0.69 CMA1 (0.53) KDM4EHSD17B10ELANECMA1CTRC
SCHEMBL9137129 0.67 HDAC3 (0.53) KDM4EMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL7965688 0.66 KDM4E (0.45) KDM4EHSD17B10ELANEHPGDALDH1A1
SCHEMBL6241617 0.66 KDM4E (0.44) KDM4EHSD17B10MEN1KMT2AELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed